The United Kingdom and the United States have established a key bilateral deal that will preserve zero import taxes on UK medicine exports being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to raise expenditure on drugs through the public health system. This pledge secures that tariffs on these key products will stay at zero for a duration of 36 months.
This agreement comes after earlier threats to significantly raise tariffs on patented drug products, with figures discussed up to one hundred percent.
"This deal between the Britain bolsters the global environment for cutting-edge drugs and establishes much-needed equity to American-British drug exports," a statement noted.
Trade Importance
Drugs constitute one of the UK's biggest exports to the United States, which is easily the primary buyer for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of the third quarter, the UK exported pharmaceutical products worth billions to the US. This amount made up 17.4% of total UK exports in that period.
"This guarantee secures work, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for biotech and pharma," a government official commented.
Key British Pledges
The pact involves several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a target to raise overall health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must return to the NHS to prevent overspending will be capped at 15%. Previously, refunds exceeded twenty percent.
Broader Context
The pact takes place against a long-running row between the drug companies and the UK government over medicine costs and approval rates.
This friction were intensified by claims that US consumers were charged several times more for the equivalent treatments than people in the other developed nations.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while major expansions have been announced toward projects in the United States.
A senior figure stated that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a share of its total funding over the last ten years.
